Literature DB >> 28302862

Arresting the Development of Addiction: The Role of β-Arrestin 2 in Drug Abuse.

Kirsten A Porter-Stransky1, David Weinshenker2.   

Abstract

The protein β-arrestin (βarr) 2 directly interacts with receptors and signaling pathways that mediate the behavioral effects of drugs of abuse, making it a prime candidate for therapeutic interventions. βarr2 drives desensitization and internalization of G protein-coupled receptors, including dopamine, opioid, and cannabinoid receptors, and it can also trigger G protein-independent intracellular signaling. βarr2 mediates several drug-induced behaviors, but the relationship is complex and dependent on the type of behavior (e.g., psychomotor versus reward), the class of drug (e.g., psychostimulant versus opioid), and the circuit being interrogated (e.g., brain region, cell type, and specific receptor ligand). Here we discuss the current state of research concerning the contribution of βarr2 to the psychomotor and rewarding effects of addictive drugs. Next we identify key knowledge gaps and suggest new tools and approaches needed to further elucidate the neuroanatomical substrates and neurobiological mechanisms to explain how βarr2 modulates behavioral responses to drugs of abuse, as well as its potential as a therapeutic target.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28302862      PMCID: PMC5443318          DOI: 10.1124/jpet.117.240622

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  83 in total

1.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

2.  Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase.

Authors:  Sunila Mahavadi; Wimolpak Sriwai; Jiean Huang; John R Grider; Karnam S Murthy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-01-09       Impact factor: 4.052

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

Review 4.  The physiological relevance of functional selectivity in dopamine signalling.

Authors:  N M Urs; M G Caron
Journal:  Int J Obes Suppl       Date:  2014-07-08

5.  Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.

Authors:  Laura M Bohn; Robert J Lefkowitz; Marc G Caron
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

6.  Morphine side effects in beta-arrestin 2 knockout mice.

Authors:  Kirsten M Raehal; Julia K L Walker; Laura M Bohn
Journal:  J Pharmacol Exp Ther       Date:  2005-05-25       Impact factor: 4.030

7.  β-Arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol.

Authors:  Karl Björk; Valeria Tronci; Annika Thorsell; Gianluigi Tanda; Natalie Hirth; Markus Heilig; Anita C Hansson; Wolfgang H Sommer
Journal:  Psychopharmacology (Berl)       Date:  2013-06-19       Impact factor: 4.530

8.  Decreased immunodensities of micro-opioid receptors, receptor kinases GRK 2/6 and beta-arrestin-2 in postmortem brains of opiate addicts.

Authors:  Marcel Ferrer-Alcón; Romano La Harpe; Jesús A García-Sevilla
Journal:  Brain Res Mol Brain Res       Date:  2004-02-05

9.  Morphine-induced mu opioid receptor trafficking enhances reward yet prevents compulsive drug use.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  EMBO Mol Med       Date:  2011-06-08       Impact factor: 12.137

Review 10.  The mechanistic classification of addictive drugs.

Authors:  Christian Lüscher; Mark A Ungless
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

View more
  12 in total

1.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.

Authors:  Lauren M Slosky; Yushi Bai; Krisztian Toth; Caroline Ray; Lauren K Rochelle; Alexandra Badea; Rahul Chandrasekhar; Vladimir M Pogorelov; Dennis M Abraham; Namratha Atluri; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick Maloney; Hong Yuan; Zibo Li; William C Wetsel; Anthony B Pinkerton; Lawrence S Barak; Marc G Caron
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

2.  Loss of β-arrestin2 in D2 cells alters neuronal excitability in the nucleus accumbens and behavioral responses to psychostimulants and opioids.

Authors:  Kirsten A Porter-Stransky; Alyssa K Petko; Saumya L Karne; L Cameron Liles; Nikhil M Urs; Marc G Caron; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2019-08-23       Impact factor: 4.280

Review 3.  Pharmacogenetics of Methadone Response.

Authors:  Francina Fonseca; Marta Torrens
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

4.  Age-dependent effects of dopamine receptor inactivation on cocaine-induced behaviors in male rats: Evidence of dorsal striatal D2 receptor supersensitivity.

Authors:  Cynthia A Crawford; Angie Teran; Goretti I Ramirez; Caitlin G Katz; Alena Mohd-Yusof; Shannon E Eaton; Vanessa Real; Sanders A McDougall
Journal:  J Neurosci Res       Date:  2019-07-15       Impact factor: 4.164

5.  Sex-specific role for serotonin 5-HT2A receptor in modulation of opioid-induced antinociception and reward in mice.

Authors:  Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2022-02-17       Impact factor: 5.273

6.  Chronic Methadone Use Alters the CD8+ T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli.

Authors:  Claire Mazahery; Bryan L Benson; Angélica Cruz-Lebrón; Alan D Levine
Journal:  J Immunol       Date:  2020-01-22       Impact factor: 5.422

7.  β-Arrestin 2 (ARRB2) Polymorphism is Associated With Adverse Consequences of Chronic Heroin Use.

Authors:  Klevis K Karavidha; Margit Burmeister; Mark K Greenwald
Journal:  Am J Addict       Date:  2021-03-30

8.  Dopamine D2 receptor modulates Wnt expression and control of cell proliferation.

Authors:  Fei Han; Prasad Konkalmatt; Chaitanya Mokashi; Megha Kumar; Yanrong Zhang; Allen Ko; Zachary J Farino; Laureano D Asico; Gaosi Xu; John Gildea; Xiaoxu Zheng; Robin A Felder; Robin E C Lee; Pedro A Jose; Zachary Freyberg; Ines Armando
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

9.  β-arrestin 2 attenuates lipopolysaccharide-induced liver injury via inhibition of TLR4/NF-κB signaling pathway-mediated inflammation in mice.

Authors:  Meng-Ping Jiang; Chun Xu; Yun-Wei Guo; Qian-Jiang Luo; Lin Li; Hui-Ling Liu; Jie Jiang; Hui-Xin Chen; Xiu-Qing Wei
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

10.  Beta-arrestin 1 regulation of reward-motivated behaviors and glutamatergic function.

Authors:  Nitish Mittal; Ani Minasyan; Nicole Romaneschi; Joshua K Hakimian; Gabriel Gonzalez-Fernandez; Ralph Albert; Nina Desai; Ian A Mendez; Timothy Schallert; Sean B Ostlund; Wendy Walwyn
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.